Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Leukemia, Myeloid, Acute × RG7388 × Clear all

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 79 Azacitidine 39 Daunorubicin 38 fludarabine 24 Idarubicin 24 Etoposide 24 Cyclophosphamide 23 venetoclax 22 Mitoxantrone 21 Decitabine 18 Busulfan 16 Methotrexate 14 Melphalan 10 Gemtuzumab 10 Whole-Body Irradiation 9 Peripheral Blood Stem Cell Transplantation 8 Granulocyte Colony-Stimulating Factor 8 gilteritinib 7 fludarabine phosphate 7 Tretinoin 7 Radiotherapy 7 Filgrastim 7 Drug Therapy 7 Cyclosporine 7 Tacrolimus 6 Mycophenolic Acid 6 Homoharringtonine 6 Antilymphocyte Serum 6 quizartinib 5 Stem Cell Transplantation 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02545283 2022-01-11

MIRROS

Hoffmann-La Roche

Phase 3 Terminated

447 enrolled 24 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡